Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Mallinckrodt
Colorcon
Baxter
McKesson
Johnson and Johnson

Last Updated: December 3, 2022

Tivozanib hydrochloride - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


What are the generic drug sources for tivozanib hydrochloride and what is the scope of patent protection?

Tivozanib hydrochloride is the generic ingredient in one branded drug marketed by Aveo Pharms and is included in one NDA. There are two patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Tivozanib hydrochloride has forty-six patent family members in twenty-four countries.

One supplier is listed for this compound.

Summary for tivozanib hydrochloride
Recent Clinical Trials for tivozanib hydrochloride

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Genentech, Inc.Phase 1/Phase 2
Aveo Oncology PharmaceuticalsPhase 1/Phase 2
University of FloridaPhase 1/Phase 2

See all tivozanib hydrochloride clinical trials

Pharmacology for tivozanib hydrochloride
Drug ClassKinase Inhibitor
Mechanism of Action Tyrosine Kinase Inhibitors

US Patents and Regulatory Information for tivozanib hydrochloride

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Aveo Pharms FOTIVDA tivozanib hydrochloride CAPSULE;ORAL 212904-002 Mar 10, 2021 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Aveo Pharms FOTIVDA tivozanib hydrochloride CAPSULE;ORAL 212904-001 Mar 10, 2021 RX Yes No See Plans and Pricing See Plans and Pricing Y Y See Plans and Pricing
Aveo Pharms FOTIVDA tivozanib hydrochloride CAPSULE;ORAL 212904-001 Mar 10, 2021 RX Yes No See Plans and Pricing See Plans and Pricing See Plans and Pricing
Aveo Pharms FOTIVDA tivozanib hydrochloride CAPSULE;ORAL 212904-002 Mar 10, 2021 RX Yes Yes See Plans and Pricing See Plans and Pricing Y Y See Plans and Pricing
Aveo Pharms FOTIVDA tivozanib hydrochloride CAPSULE;ORAL 212904-002 Mar 10, 2021 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for tivozanib hydrochloride

Country Patent Number Title Estimated Expiration
Japan 3602513 See Plans and Pricing
Japan WO2004035572 N−{2−クロロ−4−[(6,7−ジメトキシ−4−キノリル)オキシ]フェニル}−N’−(5−メチル−3−イソキサゾリル)ウレアの塩の結晶形 See Plans and Pricing
Brazil 0209216 See Plans and Pricing
Mexico PA03009662 DERIVADOS DE QUINOLINA Y DERIVADOS DE QUINAZOLINA QUE TIENEN GRUPOS AZOLILO. (QUINOLINE DERIVATIVE HAVING AZOLYL GROUP AND QUINAZOLINE DERIVATIVE.) See Plans and Pricing
Denmark 1382604 See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for tivozanib hydrochloride

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1382604 122018000018 Germany See Plans and Pricing PRODUCT NAME: TIVOZANIB ODER EIN SALZ ODER SOLVAT HIERVON; REGISTRATION NO/DATE: EU/1/17/1215 20170824
1382604 300927 Netherlands See Plans and Pricing DETAILS ASSIGNMENT: CHANGE OF OWNER(S), CHANGE OF OWNER(S) NAME
1382604 C201830013 Spain See Plans and Pricing PRODUCT NAME: TIVOZANIB O UNA SAL O SOLVATO DEL MISMO, EN PARTICULAR, EL HIDROCLORURO MONOHIDRATO; NATIONAL AUTHORISATION NUMBER: EU/1/17/1215; DATE OF AUTHORISATION: 20170824; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/17/1215; DATE OF FIRST AUTHORISATION IN EEA: 20170824
1382604 18C1006 France See Plans and Pricing PRODUCT NAME: TIVOZANIB OU UN DE SES SELS OU DE SES SOLVATES,EN PARTICULIER LE CHLORHYDRATE MONOHYDATE; REGISTRATION NO/DATE: EU/1/17/1215 20170829
1382604 CR 2018 00007 Denmark See Plans and Pricing PRODUCT NAME: TIVOZANIB ELLER ET SALT ELLER SOLVAT DERAF, SAERLIGT HYDROCHLORIDMONOHYDRATET; REG. NO/DATE: EU/1/17/1215 20170829
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
AstraZeneca
Colorcon
Baxter
McKinsey
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.